Combined biomarker analysis shows promise as a tissue agnostic response predictor for immunotherapy-based treatment
Precision oncology

Combined biomarker analysis shows promise as a tissue agnostic response predictor for immunotherapy-based treatment

Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone 

Read more
Exploratory analysis of IMpower010 confirms that ctDNA is prognostic for adjuvant atezolizumab in NSCLC
Lung and other thoracic tumours

Exploratory analysis of IMpower010 confirms that ctDNA is prognostic for adjuvant atezolizumab in NSCLC

However, improved outcomes are reported in PD-L1-positive patients only irrespective of post-operative and post-chemotherapy ctDNA status, calling into question its predictive value

Read more

Don't miss

  • Opening session
    7 December 2022, 13:15-13:50, Room B
  • Proffered paper session
    7 December 2022, 14:05-15:40, Room B
  • Mini Oral session
    8 December 2022, 9:00-10:30, Room C

EDITORIAL

Congress Highlights

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.